- Home
- BIAF vs HCWB Comparison
BIAF vs HCWB Comparison
Compare BIAF & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- HCWB
- Stock Information
- Founded
- BIAF 2014
- HCWB 2018
- Country
- BIAF United States
- HCWB United States
- Employees
- BIAF N/A
- HCWB N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- HCWB Health Care
- Exchange
- BIAF Nasdaq
- HCWB Nasdaq
- Market Cap
- BIAF 7.6M
- HCWB 8.7M
- IPO Year
- BIAF 2022
- HCWB 2021
- Fundamental
- Price
- BIAF $3.24
- HCWB $4.88
- Analyst Decision
- BIAF Hold
- HCWB Strong Buy
- Analyst Count
- BIAF 1
- HCWB 1
- Target Price
- BIAF N/A
- HCWB $35.00
- AVG Volume (30 Days)
- BIAF 7.6M
- HCWB 1.3M
- Earning Date
- BIAF 11-13-2025
- HCWB 11-13-2025
- Dividend Yield
- BIAF N/A
- HCWB N/A
- EPS Growth
- BIAF N/A
- HCWB N/A
- EPS
- BIAF N/A
- HCWB N/A
- Revenue
- BIAF $7,681,059.00
- HCWB $832,841.00
- Revenue This Year
- BIAF N/A
- HCWB $178.64
- Revenue Next Year
- BIAF $20.04
- HCWB N/A
- P/E Ratio
- BIAF N/A
- HCWB N/A
- Revenue Growth
- BIAF 4.99
- HCWB N/A
- 52 Week Low
- BIAF $2.34
- HCWB $2.77
- 52 Week High
- BIAF $67.12
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- BIAF 53.34
- HCWB 49.16
- Support Level
- BIAF $2.36
- HCWB $3.66
- Resistance Level
- BIAF $7.29
- HCWB $4.13
- Average True Range (ATR)
- BIAF 0.63
- HCWB 0.19
- MACD
- BIAF -0.30
- HCWB 0.02
- Stochastic Oscillator
- BIAF 23.73
- HCWB 52.79
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.